Sanofi enlists Emcure for cancer-drug marketing in India

Shailesh Ayyangar

Sanofi's ($SNY) known for its emerging-markets prowess, but we all need a little help sometimes. To aid it with marketing its oncology lineup in India, the French drugmaker has brought on local company Emcure Pharmaceuticals, PMLiVE reports. Emcure will be responsible for drugs Taxotere, Jevtana, Fludara and Fasturtec, and doctors and patients "will now have access--under one roof--to one of the most comprehensive and complementing oncology portfolios in India," Shailesh Ayyangar, head of Sanofi's Indian subsidiary, told the publication. Report | More

Suggested Articles

Creating a relevant online health user experience has its payoffs — for both the user and the brand. Here’s why.

Sanofi's new strategy delivered for the drugmaker in the third quarter as Dupixent posted blockbuster sales and flu vaccines set a revenue record.

Catalent has acquired Bone Therapeutics' cell and gene therapy site in Gosselies, Belgium, to add to its growing "center of excellence" there.